We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Inflammation Marker Linked to Increased Cancer Death Risk

By LabMedica International staff writers
Posted on 28 Nov 2012
The measurement of blood levels of high-sensitive C-reactive protein in apparently cancer-free men could potentially help identify those at increased risk for death from cancer.

High-sensitive C-reactive protein (hs-CRP) is an important marker of inflammation has been linked to the initiation and progression of several types of cancer, as well as to the progression of atherosclerosis and cardiovascular disease. More...


Scientists at the Seoul National University Hospital (South Korea) retrospectively analyzed data from 33,556 individuals who had completed medical checkups and had been screened for blood hs-CRP at a health-screening center between May 1995 and December 2006. The average follow-up was 9.4 years, and during that time, 1,054 deaths from all causes and 506 deaths from cancer were recorded.

The hs-CRP levels were measured with a highly sensitive latex-enhanced immunoassay run on an automated chemistry analyzer (Hitachi; Tokyo, Japan). The investigators adjusted for several variables, including age, diabetes, smoking status and exercise habits and found that men with the highest level of hs-CRP in their blood, 3 mg /L or more, were 38% more likely to have died from any cause compared with men with the lowest hs-CRP level of 1 mg/L or less. They were also 61% more likely to have died from cancer. For women, after adjusting for a number of variables, no statistically significant association was observed for hs-CRP level and death from any cause or death from cancer.

Through analysis of associations between hs-CRP levels and site-specific cancers, the scientists found that a significant relationship existed only for lung cancer. After adjusting for multiple variables, individuals with the highest hs-CRP level were more than twice as likely to die from lung cancer compared with those with the lowest hs-CRP level. The association between hs-CRP levels and all-cause mortality and cancer mortality was stronger in lean individuals compared with those who were overweight.

Minseon Park, MD, PhD, MPH, the senior author of the study said, "We wanted to determine whether there was a relationship between a well-established marker of inflammation, high-sensitive C-reactive protein, and death from all causes, death from cancer or death from a site-specific cancer in Koreans." The study was published in the November 2012 edition of the journal Cancer Epidemiology, Biomarkers & Prevention.

Related Links:

Seoul National University Hospital
Hitachi



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.